What specific Sun Pharma products are being recalled in the US?

Sun Pharma's US division is recalling fluocinolone acetonide solution and certain batches of Clindamycin Phosphate USP due to manufacturing issues.

Why is Cipla USA recalling its Lanreotide Injection?

Cipla USA is recalling 15,221 syringes of Lanreotide Injection because of the presence of particulate matter.

What is the difference between a Class II and Class III drug recall?

A Class III recall is for products where use is not likely to cause adverse health consequences, while a Class II recall is for products that may cause temporary or medically reversible health consequences.

Home / Business and Economy / Pharma Giants Recall US Drugs Over Quality Issues

Pharma Giants Recall US Drugs Over Quality Issues

26 Jan

•

Summary

Sun Pharma recalls over 26,000 bottles of dandruff medication.
Cipla recalls 15,221 syringes of Lanreotide Injection.
Recalls stem from manufacturing issues like impurities and particulate matter.

Pharma Giants Recall US Drugs Over Quality Issues

Two major pharmaceutical companies, Sun Pharmaceutical Industries and Cipla Ltd, are currently recalling products in the United States due to manufacturing-related concerns. Sun Pharma's US-based division initiated a Class III nationwide recall on December 30, 2025, for 24,624 bottles of fluocinolone acetonide solution, citing failed impurity and degradation specifications. This recall is not expected to cause adverse health consequences.

Additionally, Sun Pharma initiated a Class III recall on November 26, 2025, for certain batches of Clindamycin Phosphate USP, used to treat acne vulgaris, due to out-of-specification results for total impurities and assay. In a separate action, Cipla USA, Inc. began a Class II nationwide recall on January 2, 2026, for 15,221 syringes of Lanreotide Injection, 120 mg/0.5 mL. This recall is due to the presence of particulate matter, which could lead to temporary or medically reversible health consequences.